Preschool Children's Color Combination Preferences for Clothing

Family Relations and Child Developmen

The implementation of the CLaMS Lagrangian transport core into the chemistry climate model EMAC 2.40.1: application on age of air and transport of long-lived trace species

Lagrangian transport schemes have proven to be useful tools for modelling stratospheric trace gas transport since they are less diffusive than classical Eulerian schemes and therefore especially well suited for maintaining steep tracer gradients. Here, we present the implementation of the full-Lagrangian transport core of the Chemical Lagrangian Model of the Stratosphere (CLaMS) into the ECHAM/MESSy Atmospheric Chemistry model (EMAC). We performed a ten-year time-slice simulation to evaluate the coupled model system EMAC/CLaMS. Simulated zonal mean age of air distributions are compared to age of air derived from airborne measurements, showing a good overall representation of the stratospheric circulation. Results from the new Lagrangian transport scheme are compared to tracer distributions calculated with the standard flux-form semi-Lagrangian (FFSL) transport scheme in EMAC. The differences in the resulting tracer distributions are most pronounced in the regions of strong transport barriers. The polar vortices are presented as an example and simulated trace gas distributions are compared to satellite measurements. The analysis of CFC-11, N2O, CH4, and age of air in the polar vortex regions shows that the CLaMS Lagrangian transport scheme produces a stronger, more realistic transport barrier at the edge of the polar vortex than the FFSL transport scheme of EMAC. Differences in simulated age of air range up to one year in the Arctic polar vortex in late winter/early spring. The new coupled model system EMAC/CLaMS thus constitutes a suitable tool for future model studies of stratospheric tracer transport

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. CheckMate 744, a phase 2 study for CAYA (aged 5-30 years) with R/R cHL, evaluated a risk-stratified, response-adapted approach with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response. Risk stratification was primarily based on time to relapse, prior treatment, and presence of B symptoms. We present the primary analysis of the standard-risk cohort. Data from the low-risk cohort are reported separately. Patients received 4 induction cycles with nivolumab plus BV; those without CMR (Deauville score &gt;3, Lugano 2014) received BV plus bendamustine intensification. Patients with CMR after induction or intensification proceeded to consolidation (high-dose chemotherapy/auto-HCT per protocol). Primary end point was CMR any time before consolidation. Forty-four patients were treated. Median age was 16 years. At a minimum follow-up of 15.6 months, 43 patients received 4 induction cycles (1 discontinued), 11 of whom received intensification; 32 proceeded to consolidation. CMR rate was 59% after induction with nivolumab plus BV and 94% any time before consolidation (nivolumab plus BV ± BV plus bendamustine). One-year progression-free survival rate was 91%. During induction, 18% of patients experienced grade 3/4 treatment-related adverse events. This risk-stratified, response-adapted salvage strategy had high CMR rates with limited toxicities in CAYA with R/R cHL. Most patients did not require additional chemotherapy (bendamustine intensification). Additional follow-up is needed to confirm durability of disease control. This trial was registered at www.clinicaltrials.gov as #NCT02927769.</p

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. CheckMate 744, a phase 2 study for CAYA (aged 5-30 years) with R/R cHL, evaluated a risk-stratified, response-adapted approach with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response. Risk stratification was primarily based on time to relapse, prior treatment, and presence of B symptoms. We present the primary analysis of the standard-risk cohort. Data from the low-risk cohort are reported separately. Patients received 4 induction cycles with nivolumab plus BV; those without CMR (Deauville score &gt;3, Lugano 2014) received BV plus bendamustine intensification. Patients with CMR after induction or intensification proceeded to consolidation (high-dose chemotherapy/auto-HCT per protocol). Primary end point was CMR any time before consolidation. Forty-four patients were treated. Median age was 16 years. At a minimum follow-up of 15.6 months, 43 patients received 4 induction cycles (1 discontinued), 11 of whom received intensification; 32 proceeded to consolidation. CMR rate was 59% after induction with nivolumab plus BV and 94% any time before consolidation (nivolumab plus BV ± BV plus bendamustine). One-year progression-free survival rate was 91%. During induction, 18% of patients experienced grade 3/4 treatment-related adverse events. This risk-stratified, response-adapted salvage strategy had high CMR rates with limited toxicities in CAYA with R/R cHL. Most patients did not require additional chemotherapy (bendamustine intensification). Additional follow-up is needed to confirm durability of disease control. This trial was registered at www.clinicaltrials.gov as #NCT02927769.</p

Changing times: tactics

info:eu-repo/semantics/publishedVersio

Multiomics in the central Arctic Ocean for benchmarking biodiversity change

Multiomics approaches need to be applied in the central Arctic Ocean to benchmark biodiversity change and to identify novel species and their genes. As part of MOSAiC, EcoOmics will therefore be essential for conservation and sustainable bioprospecting in one of the least explored ecosystems on Earth

A variational data assimilation system for soil–atmosphere flux estimates for the Community Land Model (CLM3.5)

This paper presents the development and implementation of a spatio-temporal variational data assimilation system (4D-var) for the soil–vegetation–atmosphere transfer model "Community Land Model" (CLM3.5), along with the development of the adjoint code for the core soil–atmosphere transfer scheme of energy and soil moisture. The purpose of this work is to obtain an improved estimation technique for the energy fluxes (sensible and latent heat fluxes) between the soil and the atmosphere. Optimal assessments of these fluxes are neither available from model simulations nor measurements alone, while a 4D-var data assimilation has the potential to combine both information sources by a Best Linear Unbiased Estimate (BLUE). The 4D-var method requires the development of the adjoint model of the CLM which is established in this work. The new data assimilation algorithm is able to assimilate soil temperature and soil moisture measurements for one-dimensional columns of the model grid. Numerical experiments were first used to test the algorithm under idealised conditions. It was found that the analysis delivers improved results whenever there is a dependence between the initial values and the assimilated quantity. Furthermore, soil temperature and soil moisture from in situ field measurements were assimilated. These calculations demonstrate the improved performance of flux estimates, whenever soil property parameters are available of sufficient quality. Misspecifications could also be identified by the performance of the variational scheme